("Sopheon" or the "Company")
Issue of Equity - Option Exercise
Sopheon plc, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, announces that, following the exercise of options by current and former employees, it has issued and allotted 750 new Ordinary Shares of 20 pence each in the Company ("Ordinary Shares"). Application will be made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 4 September 2020.
The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. The total number of Ordinary Shares in issue following Admission will be 10,202,888. The Company does not hold any shares in treasury. Accordingly, the figure of 10,202,888 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information contact:
Barry Mence, Chairman
Arif Karimjee, CFO
+ 44 (0) 1276 919 560
Carl Holmes/Giles Rolls (Corporate Finance)
Alice Lane (ECM)
+ 44 (0) 20 7220 0500
About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.
This information is provided by RNS, the news service of the London Stock Exchange
. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom
. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected]
or visit www.rns.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange